Pre-market Hot Trades in US Stocks

Bloom Energy is down 4.37% in pre-market trading. Based on recent key news:

1. On July 25, Bloom Energy fell 7.23% during the day as rumors of a deal in Panama failed to boost the stock price, with analysts maintaining a buy rating. The stock price dropped about 8%, indicating a lukewarm market reaction to the rumors.

2. On July 26, Bloom Energy's second-quarter earnings report could serve as a strong catalyst for the stock price. The market expects the report to show accelerated business growth, potentially driving the stock price up.

3. On July 27, Bloom Energy's Schaeffer's volatility score was 85, indicating that the stock has exceeded options traders' volatility expectations over the past year, reflecting high market expectations for its volatility. Investment in clean energy is accelerating, and demand for data centers is rising.

Teradyne is down 4.35% in pre-market trading. Based on recent key news:

1. On July 25, Teradyne's semiconductor testing peer Cohu reported a loss, and the U.S. Department of Commerce's restrictions on semiconductor equipment exports to China did not hinder Teradyne's growth. Despite the restrictions, Teradyne achieved a year-on-year revenue growth of 87.04% and a 17 percentage point expansion in profit margins. The stock's 52 times forward P/E ratio makes future guidance particularly important.

2. On July 27, Nvidia's high prices for chips and related connectors have driven demand for AI server-specific infrastructure. About 70% of Teradyne's revenue is AI-related, which has led to high market expectations for its future performance.

3. On July 27, analysts noted that Teradyne is expected to perform well in its upcoming second-quarter earnings report on July 29, with projected revenue growth of 87% and net income growth of 303%. This further boosts market confidence in its future performance. Strong AI demand and an optimistic outlook for the semiconductor industry.

Top Gainers in Pre-market US Stocks

C3is is up 115.43% in pre-market trading. Based on recent key news:

1. On July 27, C3is announced a public offering at a price of $0.52 per unit, with expected total proceeds of approximately $6 million. This move has increased market confidence in the company's liquidity, driving the stock price up. Source: Reuters

2. On July 25, C3is executed a 1-for-7 reverse stock split to regain compliance and expand its fleet, with adjusted net income in the first quarter surging 358% to $5.5 million. This financial performance has enhanced investor confidence in the company's growth potential. Source: Reuters

3. On July 27, C3is entered the U.S. capital market through an SEC-registered statement and underwriting of a public offering, utilizing equity and warrant structures to fund its operations and growth plans. This move further solidifies the company's position in the market. Source: Reuters Industry investment peaks, with significant liquidity flow Inlif pre-market rose by 36.16%. Based on recent key news:

4. On July 24, the Securities and Exchange Commission announced that Inlif disclosed new financial information, showing significant improvement in the company's performance, driving a substantial increase in stock price.

5. On July 25, the European Investment Bank announced the postponement of loan payments to Brenmiller Energy, alleviating market concerns about the company's financial pressure, indirectly affecting the performance of related industry stocks.

6. On July 28, Robo.ai Inc. fell by 6.3% in pre-market trading after rising 14% on Monday, reflecting market concerns about the volatility of tech stocks. Tech stocks have been highly volatile recently, and market risks need to be monitored.

Gossamer Bio pre-market rose by 31.80%. Based on recent key news:

1. On July 28, after a meeting with the FDA, Gossamer Bio plans to submit a new drug application for seralutinib in September 2026. This move has boosted market confidence in the company's future development, driving up the stock price. Source: Benzinga

2. On July 27, the company announced the repurchase of global development and commercial rights for seralutinib from Chiesi Group, optimizing its capital structure. This news boosted investor sentiment, leading to a rise in stock price. Source: Business Wire

3. On July 27, shareholders approved the exchange of convertible notes and a reverse stock split, aimed at supporting compliance with Nasdaq's minimum bid requirements. This move further solidified the company's financial foundation, resulting in an increase in stock price. Source: Public Technologies The biopharmaceutical industry has recently seen increased policy support